



IFW

PATENT
Attorney Docket 053529-5007-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Berkley Lynch et al.**)
)
Application No. **10/537,512**) Group Art Unit: *Unassigned*
)
Filing Date: **June 3, 2005**) Examiner: *Unassigned*
)
For: **Methods for the Identification of Agents**)
 for the Treatment of Seizures,)
 Neurological Diseases, Endocrinopathies)
 and Hormonal Diseases)

United States Patent and Trademark Office
Customer Service Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

The present application is a U.S. National Phase Application of International Application No. PCT/US2003/038122, filed December 2, 2003 and published June 17, 2004 as WO 2004/051222 A2. It is cited on Form PTO-1449 as Document 5.

Applicants wish to bring the following related United States pending patent applications to the Examiner's attention:

U.S. Patent Application 10/308,163, filed December 3, 2002, and published as U.S. published application no. 2004/0106147 on June 3, 2004; and

U.S. Patent Application 10/725,189, filed December 2, 2003, and published as U.S. published application no. 2004/0204388 on October 14, 2004.

With the exception of published U.S. Applications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Dated: **March 2, 2006**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP


Sally P. Teng, Ph.D.
Registration No. 45,397

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Attorney Docket No. 053529-5007-02	Application No. 10/537,512
Applicants: Berkley Lynch <i>et al.</i>		Filing Date: June 3, 2005	
Group Art Unit: Unassigned			



PTO Form 1449

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
	1.	US 2003/0009024 A1	01/09/2003	Curtis	536	23.5	06/13/2002
	2.	US 2002/0142383 A1	10/03/2002	Merkulov <i>et al.</i>	435	69.1	04/02/2001

FOREIGN PATENT DOCUMENTS							
Document No.	Date	Country	Class	Sub-Class	Translation		
3.	WO 01/62726 A2	08/30/2001	WIPO				
4.	WO 01/62726 A3	08/30/2001	WIPO				
5.	WO 2004/051222 A2	06/17/2004	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
6.	Bajjalieh, S.M., <i>et al.</i> , "SV2, a brain synaptic vesicle protein homologous to bacterial transporters," <i>Science</i> 257:1271-1273, American Association for the Advancement of Science, Washington DC, USA (August 1992)
7.	Bajjalieh, S.M., <i>et al.</i> , "Brain contains two forms of synaptic vesicle protein 2," <i>Proc. Natl. Acad. Sci. USA</i> 90:2150-2154, National Academy of Sciences, Washington DC, USA (March 1993)
8.	Bajjalieh, S.M., <i>et al.</i> , "Differential Expression of Synaptic Vesicle Protein 2 (SV2) Isoforms," <i>J. Neurosci.</i> 14:5223-5235, The Society for Neuroscience, Washington DC, USA (September 1994)
9.	Buckley, K. and R.B. Kelly, "Identification of a Transmembrane Glycoprotein Specific for Secretory Vesicles of Neural and Endocrine Cells," <i>J. Cell Biol.</i> 100:1284-1294, The Rockefeller University Press, New York NY, USA (April 1985)
10.	Crowder, K.M., <i>et al.</i> , "Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)," <i>Proc. Natl. Acad. Sci. USA</i> 96:15268-15273, National Academy of Sciences, Washington DC, USA (December 1999)
11.	Feany, M.B., <i>et al.</i> , "The Synaptic Vesicle Protein SV2 is a Novel Type of Transmembrane Transporter," <i>Cell</i> 70:861-867, Cell Press, Cambridge MA, USA (September 1992)
12.	Fuks, B., <i>et al.</i> , "Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines," <i>Eur. J. Pharmacol.</i> 478:11-19, Elsevier B.V., Amsterdam, The Netherlands (September 2003)
13.	Hayashi, M., <i>et al.</i> , "Synaptic Vesicle Protein SV2B, but Not SV2A, is Predominantly Expressed and Associated with Microvesicles in Rat Pinealocytes," <i>J. Neurochem.</i> 71:356-365, Lippincott-Raven Publishers, Philadelphia PA, USA (July 1998)
14.	Janz, R., <i>et al.</i> , "SVOP, an Evolutionarily Conserved Synaptic Vesicle Protein, Suggests Novel Transport Functions of Synaptic Vesicles," <i>J. Neurosci.</i> 18:9269-9281, The Society for Neuroscience, Washington DC, USA (November 1998)
15.	Janz, R., <i>et al.</i> , "SV2A and SV2B Function as Redundant Ca ²⁺ Regulators in Neurotransmitter Release," <i>Neuron</i> 24:1003-1016, Cell Press, Cambridge MA, USA (December 1999)
16.	Janz, R., "Knockout Mice and SV2 Synaptic-Vesicle proteins," <i>University of Texas Health Science Center at Houston Neuroscience Research Center Newsletter</i> 7:1-8, Neuroscience Research Center, Houston TX, USA (2001)
17.	Lynch B., <i>et al.</i> , "The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam," <i>Proc. Natl. Acad. Sci. USA</i> 101:9861-9866, National Academy of Sciences, Washington DC, USA (June, 2004)
18.	Margineanu, D.G., and H. Klitgaard, "Levetiracetam: Mechanisms of Action," <i>In: Antiepileptic Drugs, 5th Edition</i> , pp. 419-427, Levy, R.H., <i>et al. eds.</i> , Lippincott Williams & Wilkins, Philadelphia PA, USA (June 2002)
19.	Noyer, M., <i>et al.</i> , "The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes," <i>Eur. J. Pharmacol.</i> 286:137-146, Elsevier B.V., Amsterdam, The Netherlands (November 1995)

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 053529-5007-02		Application No. 10/537,512	
<div style="position: relative; height: 100px;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; color: black; font-weight: bold; line-height: 1;"> OFFICE MAR 02 2005 PATENT & TRADEMARK OFFICE </div> </div> <div style="text-align: center; margin-top: 10px;"> PTO Form 1449 </div>				Applicants: Berkley Lynch <i>et al.</i>			
				Filing Date: June 3, 2005		Group Art Unit: Unassigned	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
20.	Pyle, R.A., <i>et al.</i> , "Phosphorylation of Synaptic Vesicle Protein 2 Modulates Binding to Synaptotagmin," <i>J. Biol. Chem.</i> 275:17195-17200, The American Society for Biochemistry and Molecular Biology, Inc., Bethesda MD, USA (June, 2000)						
21.	Schivell, A.E., <i>et al.</i> , "Isoform-specific, Calcium-regulated Interaction of the Synaptic Vesicle Proteins SV2 and Synaptotagmin," <i>J. Biol. Chem.</i> 271:27770-27775, The American Society for Biochemistry and Molecular Biology, Inc., Bethesda MD, USA (November 1996)						
22.	Son, Y-J. <i>et al.</i> , "The Synaptic Vesicle Protein SV2 is Complexed with an α 5-Containing Laminin on the Nerve Terminal Surface," <i>J. Biol. Chem.</i> 275:451-460, The American Society for Biochemistry and Molecular Biology, Inc., Bethesda MD, USA (January 2000)						
23.	Xu, T., and S.M. Bajjalieh, "SV2 modulates the size of the readily releasable pool of secretory vesicles," <i>Nat. Cell Biol.</i> 3:691-698, Macmillan Magazines Ltd., London, England (August 2001)						
24.	Nagase, T., <i>et al.</i> , "Prediction of the Coding Sequences of Unidentified Human Genes. XI. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ," <i>DNA Res.</i> 5:277-286, Kazusa DNA Research Institute and Universal Academy Press, Chiba, Japan (1998)						
25.	Nagase, T., <i>et al.</i> , "Genbank Accession 094841, KIAA0736 Human SV2," 2 pages, National Center for Biotechnology Information, Bethesda MD, USA (May 1, 1999)						
26.	Li, C.H., <i>et al.</i> , " β -Endorphin omission analogs: Dissociation of immunoreactivity from other biological activities," <i>Proc. Natl. Acad. Sci. USA</i> 77:3211-3214, National Academy of Sciences, Washington DC, USA (June 1980)						
27.	Miyata, T., <i>et al.</i> , "Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimaeric modelling," <i>Br. J. Haematol.</i> 88:156-165, Blackwell Scientific Publications, Oxford, England (September 1994)						
28.	Skolnick, J., and J.S. Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends Biotechnol.</i> 18:34-39, Elsevier Science Ltd., Amsterdam, The Netherlands (January 2000)						
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							